Abstract：
This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.
摘要：
本文概述了急性和慢性移植物抗宿主病（GvHD）的评估和管理。有一个重点是鲁索替尼的使用，Janus激酶（JAK）1和JAK2的选择性抑制剂，用于治疗皮质类固醇难治性和皮质类固醇依赖性GvHD。
